European Cancer Therapies Market Industry Market Size, Share and Outlook - Growth Analysis Report and Forecast Trends 2026-2030

The European cancer therapy market in 2025 stands at $61.46 billion, with expectations to grow to $83.69 billion by 2031 at a steady CAGR of 5.31%. Total direct European cancer expenditure reached €146 billion in 2023, reflecting the broader financial burden of cancer care across the region. Official bodies such as Eurostat and the European Commission's Cancer Inequalities Registry track public health spending and disease burden, while commercial market figures capture the value of therapies sold.

• •Market valued at $61.46 billion in 2025; projected to reach $83.69 billion by 2031
• •Overall direct cancer expenditure across Europe reached €146 billion in 2023
• •Market measured by commercial therapy sales; government agencies track public health costs separately

Rising cancer incidence across an aging European population is a primary catalyst for market expansion, with more patients requiring treatment each year. Increased approval and adoption of novel therapies, including immunotherapies and targeted agents, drive both higher unit volumes and premium pricing. Government and institutional investments in oncology research, alongside expanding reimbursement frameworks, further support long-term market growth.

• •Aging demographics and rising cancer incidence rates across Europe increase patient volumes
• •Growing adoption of novel therapies such as immunotherapies and targeted medicines
• •Expanding oncology R&D pipelines and supportive regulatory and reimbursement environments

The market spans multiple therapeutic areas, with prostate cancer therapeutics representing a notable segment projected to reach $6.62 billion by 2030 at a 13.5% CAGR. Western Europe, including Germany, France, and the United Kingdom, dominates market share due to advanced healthcare infrastructure and higher drug spending per capita. Eastern European nations are gradually expanding access, though disparities in cancer drug expenditure persist across countries, as documented in peer-reviewed studies using Eurostat economic indicators.

• •Prostate cancer therapeutics segment projected to reach $6.62 billion by 2030 at 13.5% CAGR
• •Western Europe leads in market share due to advanced healthcare systems and higher per-capita drug spending
• •Cross-country inequities in cancer drug access and expenditure remain a documented challenge

What are the recent trends and outlook?

Looking ahead, the market is expected to benefit from continued breakthroughs in precision medicine, including biomarker-driven treatments and combination therapies. The OECD and European Commission's joint Cancer Inequalities Registry highlights ongoing efforts to improve access and reduce geographic disparities in cancer care delivery. Long-term growth will be sustained by scientific advances, expanding indications for existing drugs, and increasing healthcare budgets allocated to oncology across European nations.

• •Precision medicine, biomarker-driven therapies, and combination regimens are reshaping treatment paradigms
• •European Commission and OECD initiatives aim to reduce cancer care inequalities across member states
• •Long-term outlook remains positive driven by scientific innovation and expanding oncology indications